JP2024504136A - 「新規な二環式ペプチド」 - Google Patents
「新規な二環式ペプチド」 Download PDFInfo
- Publication number
- JP2024504136A JP2024504136A JP2023543460A JP2023543460A JP2024504136A JP 2024504136 A JP2024504136 A JP 2024504136A JP 2023543460 A JP2023543460 A JP 2023543460A JP 2023543460 A JP2023543460 A JP 2023543460A JP 2024504136 A JP2024504136 A JP 2024504136A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- bicyclic
- alanine
- peptidomimetic
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021900114A AU2021900114A0 (en) | 2021-01-19 | Novel bicyclic peptipes | |
| AU2021900114 | 2021-01-19 | ||
| PCT/AU2022/050023 WO2022155704A1 (en) | 2021-01-19 | 2022-01-19 | Novel bicyclic peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024504136A true JP2024504136A (ja) | 2024-01-30 |
| JP2024504136A5 JP2024504136A5 (https=) | 2025-01-27 |
| JPWO2022155704A5 JPWO2022155704A5 (https=) | 2025-01-27 |
Family
ID=82548163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023543460A Pending JP2024504136A (ja) | 2021-01-19 | 2022-01-19 | 「新規な二環式ペプチド」 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240117005A1 (https=) |
| EP (1) | EP4281486A4 (https=) |
| JP (1) | JP2024504136A (https=) |
| KR (1) | KR20230146025A (https=) |
| CN (1) | CN117062842A (https=) |
| AU (1) | AU2022209878A1 (https=) |
| CA (1) | CA3208598A1 (https=) |
| IL (1) | IL304545A (https=) |
| WO (1) | WO2022155704A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121108243A (zh) * | 2025-01-03 | 2025-12-12 | 中国药科大学 | 一种非核糖体多肽化合物及其合成基因簇bnp37和应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004077062A2 (en) * | 2003-02-27 | 2004-09-10 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| JP2018537965A (ja) * | 2015-10-30 | 2018-12-27 | アフィボディ・アーベー | Pd−l1に対して親和性を有する新規ポリペプチド |
| WO2019136531A1 (en) * | 2018-01-15 | 2019-07-18 | University Of Canberra | Proteinaceous molecules and uses therefor |
| JP2019189591A (ja) * | 2018-04-27 | 2019-10-31 | 日東電工株式会社 | ヒトpd−l1結合性ペプチド |
| JP2020502238A (ja) * | 2016-12-23 | 2020-01-23 | バイスクルアールディー・リミテッド | 新規連結構造を有するペプチド誘導体 |
| WO2020128527A1 (en) * | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10585100B2 (en) * | 2015-04-30 | 2020-03-10 | Kyoto University | Method of predicting effect of treatment by PD-1/PD-L1 blockade using abnormality of PD-L1 (CD274) as index |
-
2022
- 2022-01-19 KR KR1020237027582A patent/KR20230146025A/ko active Pending
- 2022-01-19 CA CA3208598A patent/CA3208598A1/en active Pending
- 2022-01-19 EP EP22741955.3A patent/EP4281486A4/en active Pending
- 2022-01-19 AU AU2022209878A patent/AU2022209878A1/en active Pending
- 2022-01-19 JP JP2023543460A patent/JP2024504136A/ja active Pending
- 2022-01-19 CN CN202280022296.XA patent/CN117062842A/zh active Pending
- 2022-01-19 US US18/273,200 patent/US20240117005A1/en active Pending
- 2022-01-19 WO PCT/AU2022/050023 patent/WO2022155704A1/en not_active Ceased
-
2023
- 2023-07-18 IL IL304545A patent/IL304545A/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004077062A2 (en) * | 2003-02-27 | 2004-09-10 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| JP2018537965A (ja) * | 2015-10-30 | 2018-12-27 | アフィボディ・アーベー | Pd−l1に対して親和性を有する新規ポリペプチド |
| JP2020502238A (ja) * | 2016-12-23 | 2020-01-23 | バイスクルアールディー・リミテッド | 新規連結構造を有するペプチド誘導体 |
| WO2019136531A1 (en) * | 2018-01-15 | 2019-07-18 | University Of Canberra | Proteinaceous molecules and uses therefor |
| JP2019189591A (ja) * | 2018-04-27 | 2019-10-31 | 日東電工株式会社 | ヒトpd−l1結合性ペプチド |
| WO2020128527A1 (en) * | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
Non-Patent Citations (2)
| Title |
|---|
| DU W ET AL.: "KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation", CELL DEATH & DIFFERENTIATION, vol. 28, no. 4, JPN6025050831, 2 November 2020 (2020-11-02), pages 1284 - 1300, ISSN: 0005754003 * |
| SATELLI A ET AL.: "Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells", SCIENTIFC REPORTS, vol. vol.6, 28910, JPN6025050832, 1 July 2016 (2016-07-01), ISSN: 0005754004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4281486A4 (en) | 2025-01-08 |
| US20240117005A1 (en) | 2024-04-11 |
| CA3208598A1 (en) | 2022-07-28 |
| WO2022155704A1 (en) | 2022-07-28 |
| IL304545A (en) | 2023-09-01 |
| EP4281486A1 (en) | 2023-11-29 |
| AU2022209878A1 (en) | 2023-09-07 |
| CN117062842A (zh) | 2023-11-14 |
| KR20230146025A (ko) | 2023-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250002567A1 (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| US7071300B2 (en) | IGF antagonist peptides | |
| EP3054973B1 (en) | Tm4sf1 binding proteins and methods of using same | |
| US20190092822A1 (en) | BH4 Stabilized Peptides And Uses Thereof | |
| AU2019207534A1 (en) | Proteinaceous molecules and uses therefor | |
| US20110224133A1 (en) | Highly Potent Peptides To Control Cancer And Neurodegenerative Diseases | |
| US20130316958A1 (en) | Highly potent peptides to control cancer and neurodegenerative diseases | |
| JP2024504136A (ja) | 「新規な二環式ペプチド」 | |
| JP5475406B2 (ja) | Gbs毒素受容体 | |
| KR20040031031A (ko) | 면역 관련 질환 치료용 조성물 및 치료 방법 | |
| JP2025527370A (ja) | ヒストンメチルトランスフェラーゼ核局在化の新規阻害剤 | |
| WO2023077188A1 (en) | Proteinaceous molecules and uses therefor | |
| CA3006092C (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| US7589185B2 (en) | Nucleotide sequences and protein(s) encoded by such nucleotides for modulation of apoptosis | |
| US20200282010A1 (en) | Immunogenic compositions and uses therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250117 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250117 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251216 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260313 |